During a 90-day observation period after treatment, two markers of AD, amyloid-β (Aβ) and hyperphosphorylated tau (p-tau) protein, were both reduced by more than 70% in cerebrospinal fluids extracted from AD mice, and there was a significant improvement in the cognitive performance of AD mice. Here, MAPT is linked to Alzheimer disease.